SU663404A1 - Method of obtaining fibrin monomer - Google Patents
Method of obtaining fibrin monomerInfo
- Publication number
- SU663404A1 SU663404A1 SU762437992A SU2437992A SU663404A1 SU 663404 A1 SU663404 A1 SU 663404A1 SU 762437992 A SU762437992 A SU 762437992A SU 2437992 A SU2437992 A SU 2437992A SU 663404 A1 SU663404 A1 SU 663404A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- solution
- fibrin monomer
- obtaining
- acid
- thrombin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 10
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 title claims description 7
- 108010073651 fibrinmonomer Proteins 0.000 title claims description 7
- 108010049003 Fibrinogen Proteins 0.000 claims description 5
- 102000008946 Fibrinogen Human genes 0.000 claims description 5
- 108090000190 Thrombin Proteins 0.000 claims description 5
- 239000004202 carbamide Substances 0.000 claims description 5
- 229940012952 fibrinogen Drugs 0.000 claims description 5
- 229960004072 thrombin Drugs 0.000 claims description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 2
- 239000000243 solution Substances 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
II
Изобретение относитс к области медицины а именно получению аналитических препаратов и может быть использовано в биохнмии, физиологии и фармакологии.This invention relates to the field of medicine, namely to the preparation of analytical preparations and can be used in biochemistry, physiology and pharmacology.
Известен способ получени фибрин-мономера путем добавлени к раствору фибриногена раствора тромбина, отделени образовавшегос сгустка и обработки его раствором мочевины .A known method for producing a fibrin monomer is by adding a thrombin solution to the fibrinogen solution, separating the clot formed and treating it with a urea solution.
Однако такой способ длителен (до 3 суток ), а выход целевого продукта невысокий1-10% .However, this method is long (up to 3 days), and the yield of the target product is low1-10%.
Целью изобретени вл етс повышение выхода целевого продукта и ускорение способа .The aim of the invention is to increase the yield of the target product and accelerate the method.
Это цель достигаетс тем, что перед добавлением раствора тромбина к раствору фибриногена добавл ют монойодацетамид или монойодуксусную кислоту, в концентрации 0,001-0,05 М на 1 л раствора и эпсилонаминокапроновую кислоту.This goal is achieved by adding monoiodoacetamide or monoiodoacetic acid to a solution of fibrinogen before the addition of the thrombin solution, in a concentration of 0.001-0.05 M per 1 liter of the solution and epsilonaminocaproic acid.
Способ осуществл ют следующим образом.The method is carried out as follows.
К 1000 мл 0,2%-ного раствора фибриногена добавл ют монойодуксусную кислоту или монойодацетамид в конечной концентрации 0,001-0,05 М и эпснлонаминокапроновую кнслоту в концентрации 0,3-0,6% с последующим добавлением к фибриногену 100-200 ед. активности тромбина в объеме 10 мл физиологического раствора. Образующийс сгусток собирают стекл нной папочкой, отжимают, промывают Б физиологическом растворе и перенос т в 100 мл 10-20%-ного раствора мочевины в ацетатном буфере (рН 5,2). Сгусток раствор ют , например, с помощью магнитной мешалки при комнатной температуре. После растворени сгустка раствор белка разбавл ют 800 мл физиологического раствора и добавл ют 200 мл буфера Палитча. Сгусток снова собирают , отжимают, промывают в физиологическом растворе и раствор ют в минимальном объеме раствора мочевины. Эту операцию повтор ют 3-4 раза. В результате получают 50-100 мл р,5-1%-ного раствора фибринмономера , который хран т при 4-5 С. Все операцин по выделению фибрин-мономера можно проводить при комнатной температуре .To 1000 ml of a 0.2% fibrinogen solution are added monoiodoacetic acid or monoiodoacetamide at a final concentration of 0.001-0.05 M and an esnlonaminocaproic acid concentration of 0.3-0.6% with subsequent addition of 100-200 units to fibrinogen. activity of thrombin in a volume of 10 ml of saline. The resulting clot is collected with a glass dad, wrung out, washed with B saline solution and transferred to 100 ml of 10-20% urea solution in acetate buffer (pH 5.2). The clot is dissolved, for example, using a magnetic stirrer at room temperature. After the clot has dissolved, the protein solution is diluted with 800 ml of physiological saline and 200 ml of Palitch buffer is added. The clot is collected again, drained, washed in saline and dissolved in a minimum volume of urea solution. This operation is repeated 3-4 times. The result is 50-100 ml of p, 5-1% solution of fibrin monomer, which is stored at 4-5 C. All operations for isolating fibrin monomer can be performed at room temperature.
iaiiSKu -bist jf riiaiiSKu -bist jf ri
Дл длительного (более 1,5 мес использовани полученного препарата последнюю операцию по растворению фибрин-мономера провод т не в 10-2да-ном растворе мочевины в ацетатном буфере, а в 0,025-0,002 М растворе уксусной кислоты, раствор белка замораживают и высушивают в вакууме.For a long time (more than 1.5 months of use of the obtained preparation, the last operation to dissolve the fibrin monomer is carried out not in 10-2 d-urea solution in acetate buffer, but in 0.025-0.002 M solution of acetic acid, the protein solution is frozen and dried in vacuum .
Предлагаемый способ позвол ет сократить процед)фу выделени с 3 суток до 4-6 час, увеличить выход фибрин-мономера в 5-7 раз, а также повысить степень чистоты более, чем на 2% по сравнению с известным способом. Способ осуществл ют без применени дорогосто щих ирепаратов и аппаратуры в услови х биохимических лабораторий.The proposed method allows reducing the extraction procedure from 3 days to 4-6 hours, increasing the yield of the fibrin monomer by 5-7 times, as well as increasing the degree of purity by more than 2% compared with the known method. The method is carried out without the use of expensive drugs and equipment in the conditions of biochemical laboratories.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU762437992A SU663404A1 (en) | 1976-12-30 | 1976-12-30 | Method of obtaining fibrin monomer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU762437992A SU663404A1 (en) | 1976-12-30 | 1976-12-30 | Method of obtaining fibrin monomer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU663404A1 true SU663404A1 (en) | 1979-05-25 |
Family
ID=20689814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU762437992A SU663404A1 (en) | 1976-12-30 | 1976-12-30 | Method of obtaining fibrin monomer |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU663404A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962420A (en) * | 1992-10-08 | 1999-10-05 | Bristol-Myers Squibb Company | Fibrin sealant compositions and methods for utilizing same |
| US6586573B1 (en) | 1999-02-22 | 2003-07-01 | Baxter International Inc. | Albumin-free Factor VIII formulations |
| RU2366955C2 (en) * | 2007-07-24 | 2009-09-10 | Общество с ограниченной ответственностью фирма "Технология-Стандарт" | Method for determination of fibrin monomer self-assembly time |
| RU2522237C2 (en) * | 2012-05-04 | 2014-07-10 | Общество с ограниченной ответственностью фирма "Технология-Стандарт" | Method of industrial production of fibrin-monomer from blood plasma |
| US10512674B2 (en) | 2008-11-07 | 2019-12-24 | Baxalta Incorporated | Factor VIII formulations |
-
1976
- 1976-12-30 SU SU762437992A patent/SU663404A1/en active
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962420A (en) * | 1992-10-08 | 1999-10-05 | Bristol-Myers Squibb Company | Fibrin sealant compositions and methods for utilizing same |
| US8372800B2 (en) | 1999-02-22 | 2013-02-12 | Baxter International Inc. | Albumin-free factor VIII formulations |
| US7087723B2 (en) | 1999-02-22 | 2006-08-08 | Baxter International Inc. | Albumin-free factor VIII formulations |
| US7247707B2 (en) | 1999-02-22 | 2007-07-24 | Baxter International Inc. | Albumin-free factor VIII formulations |
| US8058226B2 (en) | 1999-02-22 | 2011-11-15 | Baxter International Inc. | Albumin-free factor VIII formulations |
| US6586573B1 (en) | 1999-02-22 | 2003-07-01 | Baxter International Inc. | Albumin-free Factor VIII formulations |
| US8765665B2 (en) | 1999-02-22 | 2014-07-01 | Baxter International Inc. | Albumin-free factor VIII formulations |
| US9352027B2 (en) | 1999-02-22 | 2016-05-31 | Baxalta Incorporated | Albumin-free factor VIII formulations |
| US9669076B2 (en) | 1999-02-22 | 2017-06-06 | Baxalta Incorporated | Albumin-free factor VIII formulations |
| RU2366955C2 (en) * | 2007-07-24 | 2009-09-10 | Общество с ограниченной ответственностью фирма "Технология-Стандарт" | Method for determination of fibrin monomer self-assembly time |
| US10512674B2 (en) | 2008-11-07 | 2019-12-24 | Baxalta Incorporated | Factor VIII formulations |
| US11020459B2 (en) | 2008-11-07 | 2021-06-01 | Baxalta Incorporated | Factor VIII formulations |
| RU2522237C2 (en) * | 2012-05-04 | 2014-07-10 | Общество с ограниченной ответственностью фирма "Технология-Стандарт" | Method of industrial production of fibrin-monomer from blood plasma |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Blombäck et al. | Coagulation studies on „Reptilase”, an extract of the venom from Bothrops jararaca | |
| Kowalski et al. | An evaluation of the euglobulin method for the determination of fibrinolysis | |
| Jollès | [12] Lysozymes from rabbit spleen and dog spleen | |
| EP0244834B1 (en) | Process for producing a factor v concentrate | |
| SU663404A1 (en) | Method of obtaining fibrin monomer | |
| Etherington et al. | Nomenclature of the pepsins | |
| DE2220568C2 (en) | Affinity matrix material and its use for the purification of trypsin or trypsin-like enzymes or for their storage | |
| Jackson et al. | Separation of the tosyl arginine esterase activity from the factor X activating enzyme of Russell's viper venom | |
| EP0626070B1 (en) | Method of determining hirudin and synthetic thrombin inhibitors | |
| Bruhn et al. | Quantitative determination of plasminogen | |
| Silberman et al. | Effects of ancrod (Arvin) in mice: studies of plasma fibrinogen and fibrinolytic activity | |
| Aung-Khin et al. | Effects of Russell's viper venom on blood coagulation, platelets and the fibrinolytic enzyme system | |
| US3136703A (en) | Method for obtaining fibrinolysin | |
| US4100028A (en) | Method for purification of proteolytic enzymes | |
| Cox et al. | Chromatographic purification of human serum accelerator globulin | |
| Stein et al. | Cytologic demonstration of nucleic acids in tissue culture | |
| US5094949A (en) | Use of chymotrypsin for the inactivation of prekallikrein activator | |
| US4283530A (en) | Process for the preparation of heparin | |
| Laursen et al. | Spontaneous fibrinolysis demonstrated by immunological technique | |
| DE2047317A1 (en) | Enzymes | |
| Miller et al. | Degradation of Fibrinogen by Proteolytic Enzymes | |
| JP2645774B2 (en) | TAT stabilization method | |
| Fantl et al. | The interaction of thrombin with the plasma components of man and experimental animals. | |
| Kierszenbaum et al. | Alterations in the enzymatic activity of plasma of guinea pigs infected with Junin virus | |
| MONKHOUSE | Blood coagulation and lipid metabolism |